Beatrice Eymin

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/5894532/publications.pdf

Version: 2024-02-01

58 papers	2,885 citations	147801 31 h-index	175258 52 g-index
60 all docs	60 docs citations	60 times ranked	4137 citing authors

#	Article	IF	Citations
1	Loss of Histone H4K20 Trimethylation Occurs in Preneoplasia and Influences Prognosis of Nonâ€“Small Cell Lung Cancer. Clinical Cancer Research, 2008, 14, 7237-7245.	7.0	209
2	Human ARF binds E2F1 and inhibits its transcriptional activity. Oncogene, 2001, 20, 1033-1041.	5.9	154
3	The ARF tumor suppressor: Structure, functions and status in cancer. International Journal of Cancer, 2010, 127, 2239-2247.	5.1	148
4	Abnormal Expression of the Pre-mRNA Splicing Regulators SRSF1, SRSF2, SRPK1 and SRPK2 in Non Small Cell Lung Carcinoma. PLoS ONE, 2012, 7, e46539.	2.5	119
5	Distinct pattern of E2F1 expression in human lung tumours: E2F1 is upregulated in small cell lung carcinoma. Oncogene, 2001, 20, 1678-1687.	5.9	115
6	Acetylation and phosphorylation of SRSF2 control cell fate decision in response to cisplatin. EMBO Journal, 2011, 30, 510-523.	7.8	115
7	p14ARF induces G2 arrest and apoptosis independently of p53 leading to regression of tumours established in nude mice. Oncogene, 2003, 22, 1822-1835.	5.9	114
8	Mdm2 overexpression and p14ARF inactivation are two mutually exclusive events in primary human lung tumors. Oncogene, 2002, 21, 2750-2761.	5.9	100
9	p14^{ARF} Activates a Tip60-Dependent and p53-Independent ATM/ATR/CHK Pathway in Response to Genotoxic Stress. Molecular and Cellular Biology, 2006, 26, 4339-4350.	2.3	97
10	p27Kip1 induces drug resistance by preventing apoptosis upstream of cytochrome c release and procaspase-3 activation in leukemic cells. Oncogene, 1999, 18, 1411-1418.	5.9	86
11	Caspase-induced proteolysis of the cyclin-dependent kinase inhibitor p27Kip1 mediates its anti-apoptotic activity. Oncogene, 1999, 18, 4839-4847.	5.9	84
12	E2F1 controls alternative splicing pattern of genes involved in apoptosis through upregulation of the splicing factor SC35. Cell Death and Differentiation, 2008, 15, 1815-1823.	11.2	84
13	Role of cell cycle regulators in lung carcinogenesis. Cell Adhesion and Migration, 2010, 4, 114-123.	2.7	76
14	Upregulation of CASP genes in human tumor cells undergoing etoposide-induced apoptosis. Oncogene, 1998, 16, 2885-2894.	5.9	75
15	Human tumor suppressor p14ARF negatively regulates rRNA transcription and inhibits UBF1 transcription factor phosphorylation. Oncogene, 2006, 25, 7577-7586.	5.9	75
16	The transcription factor E2F1 and the SR protein SC35 control the ratio of pro-angiogenic versus antiangiogenic isoforms of vascular endothelial growth factor-A to inhibit neovascularization in vivo. Oncogene, 2010, 29, 5392-5403.	5.9	74
17	Proteases, proteolysis, and apoptosis. Cell Biology and Toxicology, 1998, 14, 121-132.	5.3	70
18	Circular RNAs and RNA Splice Variants as Biomarkers for Prognosis and Therapeutic Response in the Liquid Biopsies of Lung Cancer Patients. Frontiers in Genetics, 2019, 10, 390.	2.3	68

#	Article	IF	Citations
19	The role of apoptosis in the pathogenesis and treatment of diseases. European Respiratory Journal, 1996, 9, 1293-1305.	6.7	66
20	E2F1 induces apoptosis and sensitizes human lung adenocarcinoma cells to death-receptor-mediated apoptosis through specific downregulation of c-FLIPshort. Cell Death and Differentiation, 2006, 13, 260-272.	11.2	64
21	E2F-1, Skp2 and cyclin E oncoproteins are upregulated and directly correlated in high-grade neuroendocrine lung tumors. Oncogene, 2007, 26, 6927-6936.	5.9	63
22	Altered pattern of Culâ€1 protein expression and neddylation in human lung tumours: relationships with CAND1 and cyclin E protein levels. Journal of Pathology, 2007, 213, 303-310.	4.5	62
23	p14ARF promotes RB accumulation through inhibition of its Tip60-dependent acetylation. Oncogene, 2006, 25, 4147-4154.	5.9	60
24	FGF-2 promotes angiogenesis through a SRSF1/SRSF3/SRPK1-dependent axis that controls VEGFR1 splicing in endothelial cells. BMC Biology, 2021, 19, 173.	3.8	53
25	Selective inhibition of apoptosis by TPA-induced differentiation of U937 leukemic cells. Cell Death and Differentiation, 1999, 6, 351-361.	11.2	49
26	p14ARF Triggers G2 Arrest Through ERK-Mediated Cdc25C Phosphorylation, Ubiquitination and Proteasomal Degradation. Cell Cycle, 2006, 5, 759-765.	2.6	49
27	Activation of a Tip60/E2F1/ERCC1 network in human lung adenocarcinoma cells exposed to cisplatin. Carcinogenesis, 2012, 33, 320-325.	2.8	44
28	Splice Variants of the RTK Family: Their Role in Tumour Progression and Response to Targeted Therapy. International Journal of Molecular Sciences, 2017, 18, 383.	4.1	42
29	Cellular Inhibitor of Apoptosis Protein-1 (cIAP1) Can Regulate E2F1 Transcription Factor-mediated Control of Cyclin Transcription. Journal of Biological Chemistry, 2011, 286, 26406-26417.	3.4	40
30	VEGF165b, a splice variant of VEGF-A, promotes lung tumor progression and escape from anti-angiogenic therapies through a Î²1 integrin/VEGFR autocrine loop. Oncogene, 2019, 38, 1050-1066.	5.9	38
31	Contribution of the cyclin-dependent kinase inhibitor p27KIP1 to the confluence-dependent resistance of HT29 human colon carcinoma cells. , 1998, 77, 796-802.		35
32	Intercellular trafficking and enhanced in vivo antitumour activity of a non-virally delivered P27-VP22 fusion protein. Gene Therapy, 2003, 10, 314-325.	4.5	35
33	Targeting the spliceosome machinery: A new therapeutic axis in cancer?. Biochemical Pharmacology, 2021, 189, 114039.	4.4	30
34	SRSF2 is required for sodium butyrate-mediated p21WAF1 induction and premature senescence in human lung carcinoma cell lines. Cell Cycle, 2011, 10, 1968-1977.	2.6	29
35	Expression of p15 and p15.5 products in neuroendocrine lung tumours: relationship with p15INK4b methylation status. Oncogene, 2001, 20, 6587-6596.	5.9	28
36	A new function of the splicing factor SRSF2 in the control of E2F1-mediated cell cycle progression in neuroendocrine lung tumors. Cell Cycle, 2013, 12, 1267-1278.	2.6	26

#	Article	IF	Citations
37	Nuclear trafficking of EGFR by Vps34 represses Arf expression to promote lung tumor cell survival. Oncogene, 2016, 35, 3986-3994.	5.9	26
38	A VEGF-A/SOX2/SRSF2 network controls VEGFR1 pre-mRNA alternative splicing in lung carcinoma cells. Scientific Reports, 2019, 9, 336.	3.3	22
39	Nuclear translocation of IGF1R by intracellular amphiregulin contributes to the resistance of lung tumour cells to EGFR-TKI. Cancer Letters, 2018, 420, 146-155.	7.2	20
40	The sVEGFR1-i13 splice variant regulates a Î²1 integrin/VEGFR autocrine loop involved in the progression and the response to anti-angiogenic therapies of squamous cell lung carcinoma. British Journal of Cancer, 2018, 118, 1596-1608.	6.4	18
41	RNA splicing, cell signaling, and response to therapies. Current Opinion in Oncology, 2016, 28, 58-64.	2.4	16
42	Lung cancer. Cell Adhesion and Migration, 2010, 4, 107-113.	2.7	15
43	Cellular pharmacology of azatoxins (topoisomerase-II and tubulin inhibitors) in P-glycoprotein-positive and -negative cell lines. International Journal of Cancer, 1995, 63, 268-275.	5.1	14
44	p14ARF inhibits the growth of lung adenocarcinoma cells harbouring an EGFR L858R mutation by activating a STAT3-dependent pro-apoptotic signalling pathway. Oncogene, 2013, 32, 1050-1058.	5.9	13
45	Design of PEGylated Three Ligands Silica Nanoparticles for Multi-Receptor Targeting. Nanomaterials, 2021, 11, 177.	4.1	13
46	Heteromultivalent targeting of integrin Î±vÎ²3 and neuropilin 1 promotes cell survival via the activation of the IGF-1/insulin receptors. Biomaterials, 2018, 155, 64-79.	11.4	12
47	A collagen VÎ±1-derived fragment inhibits FGF-2 induced-angiogenesis by modulating endothelial cells plasticity through its heparin-binding site. Matrix Biology, 2020, 94, 18-30.	3.6	12
48	The presence of PEG on nanoparticles presenting the c[RGDfK]- and/or ATWLPPR peptides deeply affects the RTKs-AKT-GSK3Î²-eNOS signaling pathway and endothelial cells survival. International Journal of Pharmaceutics, 2019, 568, 118507.	5.2	7
49	A dedicated microarray for in-depth analysis of pre-mRNA splicing events: application to the study of genes involved in the response to targeted anticancer therapies. Molecular Cancer, 2014, 13, 9.	19.2	6
50	Far beyond anti-angiogenesis: Benefits for anti-basicFGF therapy in cancer. Biochimica Et Biophysica Acta - Molecular Cell Research, 2022, 1869, 119253.	4.1	5
51	The yin and the yang of p27Kip1 as a target for cancer therapy. European Respiratory Journal, 2004, 23, 663-664.	6.7	3
52	Low glucose microenvironment of normal kidney cells stabilizes a subset of messengers involved in angiogenesis. Physiological Reports, 2015, 3, e12253.	1.7	3
53	VEGF-A Splice Variants: Do They Play a Role in Tumor Responses to Anti-angiogenic Therapies?. , 2014, , 421-442.		3
54	ARF promotes the degradation of the Epidermal Growth Factor Receptor by the lysosome. Experimental Cell Research, 2018, 370, 264-272.	2.6	1

#	Article	IF	Citations
55	P-009 Disruption of P14ARF dependent G2 arrest signaling pathway inlung cancer. Lung Cancer, 2005, 49, S117.	2.0	0
56	B7-01: Aberrant pattern of histone H4 modification in human lung carcinoma. Journal of Thoracic Oncology, 2007, 2, S354.	1.1	0
57	D4-03: SCF protein (Skp2, CUL1) regulate the E2F1 dependent transcriptional activity and cyclin E in human lung tumors. Journal of Thoracic Oncology, 2007, 2, S400-S401.	1.1	0
58	Role of the p14ARF tumor suppressor in EGFR-mediated growth control of bronchial adenocarcinoma. European Journal of Cancer, Supplement, 2008, 6, 34.	2.2	0